Systemic treatments for basal cell carcinoma (BCC): The advent of dermato-oncology in BCC

British Journal of Dermatology

Volumn 169, Issue 1, 2013, Pages 53-57

  Ali, F R ^a   Lear, J T ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 833923; FLUOROURACIL; IMIQUIMOD; MESSENGER RNA; PLACEBO; SONIDEGIB; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BIPHENYL DERIVATIVE; BMS-833923; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SONIC HEDGEHOG PROTEIN;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ASPIRATION; BACKACHE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER INCIDENCE; DEHYDRATION; DERMATOLOGY; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPNEA; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HUMAN; HYPONATREMIA; KERATITIS; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MUSCLE CRAMP; MUSCLE SPASM; MYALGIA; NAUSEA; NONHUMAN; ONCOLOGY; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TASTE DISORDER; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; CLINICAL TRIAL (TOPIC); SKIN NEOPLASMS;

ANILIDES; ANTINEOPLASTIC AGENTS; BENZAMIDES; BIPHENYL COMPOUNDS; CARCINOMA, BASAL CELL; CLINICAL TRIALS AS TOPIC; HEDGEHOG PROTEINS; HUMANS; PYRIDINES; QUINAZOLINES; SKIN NEOPLASMS;

EID: 84879989050     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12311     Document Type: Review

References (31)

1. Madan V, Lear JT, Szeimies R-M,. Non-melanoma skin cancer. Lancet 2010; 375: 673-85.
2. Bath-Hextall F, Leonardi-Bee J, Smith C, et al,. Trends in incidence of skin basal cell carcinoma. Additional evidence from a U.K. primary care database study. Int J Cancer 2007; 121: 2105-8.
3. Diffey BL, Langtry JA,. Skin cancer incidence and the ageing population. Br J Dermatol 2005; 153: 679-80.
4. Telfer NR, Colver GB, Morton CA,. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
5. von Domarus H, Stevens PJ,. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984; 10: 1043-60.
6. Wong CS, Strange RC, Lear JT,. Basal cell carcinoma. BMJ 2003; 327: 794-8.
7. Lo JS, Snow SN, Reizner GT, et al,. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24: 715-9.
8. Snow SN, Sahl W, Lo JS, et al,. Metastatic basal cell carcinoma. Report of five cases. Cancer 1994; 73: 328-35.
9. Galioto S, Lucioni M, Pastori M, et al,. Metastatic basal cell carcinoma: two cases involving the maxillofacial area. Int J Dermatol 2012; 51: 1097-100.
10. Pfeiffer P, Hansen O, Rose C,. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer 1990; 26: 73-7.
11. Moeholt K, Aagaard H, Pfeiffer P, Hansen O,. Platinum-based cytotoxic therapy in basal cell carcinoma-a review of the literature. Acta Oncol 1996; 35: 677-82.
12. Gorlin RJ, Goltz RW,. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 1960; 262: 908-12.
13. Lear JT,. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med 2012; 366: 2225-6.
14. Lo Muzio L,. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis 2008; 3: 32.
15. Shanley S, Ratcliffe J, Hockey A, et al,. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet 1994; 50: 282-90.
16. Aszterbaum M, Rothman A, Johnson RL, et al,. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol 1998; 110: 885-8.
17. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al,. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366: 2180-8.
18. Johnson RL, Rothman AL, Xie J, et al,. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272: 1668-71.
19. Hahn H, Wicking C, Zaphiropoulous PG, et al,. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85: 841-51.
20. Epstein EH,. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008; 8: 743-54.
21. Xie J, Murone M, Luoh SM, et al,. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391: 90-2.
22. Von Hoff DD, LoRusso PM, Rudin CM, et al,. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361: 1164-72.
23. Sekulic A, Migden MR, Oro AE, et al,. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-9.
24. Wolfe CM, Green WH, Cognetta AB Jr, Hatfield HK,. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg 2012; 38: 1863-6.
25. Skvara H, Kalthoff F, Meingassner JG, et al,. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011; 131: 1735-44.
26. Rodon Ahnert J, Baselga J, Tawbi HA, et al,. A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. J Clin Oncol 2010; 28 (Suppl.): 2500.
27. Siu LL, Papadopoulos K, Alberts SR, et al,. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol 2010; 28 (Suppl.): 1501.
28. Kim J, Aftab BT, Tang JY, et al,. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013; 23: 23-34.
29. Chang AL, Oro AE,. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol 2012; 148: 1324-5.
30. Metcalfe C, de Sauvage FJ,. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011; 71: 5057-61.
31. Yauch RL, Dijkgraaf GJ, Alicke B, et al,. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326: 572-4.